AgingResearch.NewsJoin free

Inventiva Pharma

CompanyFrance

ROR

Inventiva Pharma develops 3 assets, the furthest in phase 3 (lanifibranor in metabolic dysfunction-associated steatohepatitis). Mostly small molecule acting on PPARD, PPARG and PPARA; based in France.

3
Assets
Furthest stage
Phase 3
2
Trials
2
Signals

Pipeline

3

  • lanifibranor

    Activates PPAR receptors and has anti-fibrotic effects.

    Phase 3, Small molecule, PPARD, PPARG, metabolic dysfunction-associated steatohepatitis, type 2 diabetes (Phase 2)

  • odiparcil

    Promotes glycosaminoglycan clearance.

    Phase 2, mucopolysaccharidosis type VI

  • IVA336

    Potential substrate reduction therapy.

    Stage not known

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Trials2
  • People17
  • Signals3
  • Similar companies6

Intelligence